Early adoption of lecanemab in Japan (December 2023-December 2024): Pretreatment diagnostic timelines from the DeSC claims database.
-
アブストラクト Using the Japanese DeSC claims database, we described pretreatment timelines for lecanemab initiation during early rollout (December 2023-December 2024). We identified 76 patients (mean age 74.6 years; 34.2% men) from 45 institutions. Mean time to first infusion was 103.9 days from cognitive assessment and 63.1 days from MRI. PET-to-infusion was 30.9 days, whereas cerebrospinal fluid (CSF) sampling-to-infusion was 85.8 days; the post-test interval remained longer after CSF (Bonferroni-adjusted p = 0.015). Although this claims-based snapshot may not represent all practice in Japan, it suggests that the CSF-based pathway can be associated with a longer post-test interval before treatment initiation. ジャーナル名 Journal of Alzheimer's disease : JAD Pubmed追加日 2026/4/21 投稿者 Nakashima, Saki; Sato, Kenichiro; Niimi, Yoshiki; Aso, Shotaro; Yasunaga, Hideo; Satake, Wataru; Iwatsubo, Takeshi 組織名 Department of Neurology, Graduate School of Medicine, The University of Tokyo,;Tokyo, Japan. RINGGOLD: 13143;Unit for Early and Exploratory Development, The University of Tokyo Hospital,;Tokyo, Japan. RINGGOLD: 26782;Dementia Inclusion and Therapeutics, The University of Tokyo Hospital, Tokyo,;Japan. RINGGOLD: 26782;Department of Health Services Research, Graduate School of Medicine, The;University of Tokyo, Tokyo, Japan. RINGGOLD: 13143;Department of Clinical Epidemiology and Health Economics, School of Public;Health, The University of Tokyo, Tokyo, Japan. RINGGOLD: 13143;National Institute of Neuroscience, National Center of Neurology and Psychiatry,;Tokyo, Japan. Pubmed リンク https://www.ncbi.nlm.nih.gov/pubmed/42012375/ -
お問合わせ
検索
メルマガ登録
